Core Insights - Alnylam Pharmaceuticals Inc. is recognized as a high-growth healthcare stock with strategic initiatives aimed at improving care for patients with ATTR-CM [1] - The company has been downgraded by Jefferies from Buy to Hold, with a reduced price target of $330 from $522, citing concerns over long-term growth expectations [2] Group 1: Company Initiatives - Alnylam Pharmaceuticals announced efforts to enhance early diagnosis and care coordination for ATTR-CM patients through partnerships with Viz.ai and the American Heart Association [1] - The initiatives aim to address the issues of underdiagnosis and fragmented care in the treatment of ATTR-CM [1] Group 2: Market Perception - Jefferies expressed that while the RNAi platform of Alnylam is impressive, the stock is currently "priced to perfection," indicating potential risks in long-term growth expectations [2] - The downgrade reflects concerns that the market growth and competition assumptions may be overly optimistic [2] Group 3: Company Overview - Alnylam Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics based on ribonucleic acid interference [3]